Point mutation ofKRASat codon 12, 13, 59 or 61 impairs GTPase activity, thereby upregulating cellular proliferation and carcinoma progression.10About 20 to 50% of colorectal cancers are reported to be mutatedKRASgene, and the mutation frequency depends on the grade of the tumor.11This study aimed to evaluate the KRAS gene in colon cancer tissues obtained from patients with T2DM. The gene discussed is KRAS; the disease is type 2 diabetes mellitus.